NCT01133080

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Shalvata Mental Health Center · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Double - Blind, Randomized, single centered study. The purpose of this study is to assess the feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for positive symptoms in adults suffering from schizophrenia.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Minocycline	minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
DRUG	placebo	placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.

Timeline

• Start date: 2010-06-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2010-05-28
• Last updated: 2012-01-05

Locations

2 sites across 1 country: Israel